Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HINT1 | P49773 | 3/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675379 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL19938131 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL19941365 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL19938129 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL19922943 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL19941615 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL10118076 | 0.89 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBHPGD | |
| SCHEMBL20149809 | 0.87 | HPGD (0.73) | HPGDHINT1STING1NT5EPDE3B | |
| SCHEMBL2583453 | 0.87 | HPGD (0.73) | HPGDHINT1STING1NT5EPDE3B | |
| SCHEMBL2675833 | 0.86 | RXFP1 (0.57) | PI4KAPI4K2BPI4K2API4KBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | THE JOHNS HOPKINS UNIVERSTY | 2024-01-25 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-4123031-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3283638-B1 | METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022046910-A1 | PRODRUGS OF 6-MERCAPTOPURINE | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210403978-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-30 | — | — | US | disclosed |
| US-11149296-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-6060459-A | Enhancing blood cell count with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6054441-A | Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases | PRO-NEURON, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0570519-B1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0422638-B1 | Novel inosine/guanosine derivatives | MERRELL DOW PHARMA (US) | 1995-01-18 | — | — | EP | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0423617-A1 | Inosine/Guanosine derivatives as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0423618-A1 | Inosine/guanosine derivatives as immunosuppressive agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0422638-A1 | Novel inosine/guanosine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4621076-A | GUANOSINE MONOPHOSPHATE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | PI4KA 2708/4885PI4K2B 2615/4885PI4K2A 2186/4885 |
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | PI4KA 249/4885PI4K2B 337/4885PI4K2A 459/4885 |
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | TPMT, TYMP, MTAP | PI4KA 3336/4885PI4K2B 3516/4885PI4K2A 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.